| Completed | Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line NCT02649387 | Mayo Clinic | Phase 2 |
| Terminated | Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Sm NCT02309515 | Mayo Clinic | Phase 2 |
| Completed | Curcumin and Cholecalciferol in Treating Patients With Previously Untreated Stage 0-II Chronic Lymphocytic Leu NCT02100423 | Paolo Caimi, MD | Phase 2 |
| Completed | Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphom NCT02213913 | University of Chicago | Phase 1 / Phase 2 |
| Completed | Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or NCT02005289 | Ohio State University Comprehensive Cancer Center | Phase 2 |
| Active Not Recruiting | Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patien NCT01886872 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hemato NCT01789255 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing NCT01588015 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukem NCT01351896 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia NCT01441882 | OHSU Knight Cancer Institute | Phase 2 |
| Active Not Recruiting | Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia NCT01361711 | Northwestern University | Phase 2 |
| Completed | Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia NCT01269385 | Mayo Clinic | Phase 1 / Phase 2 |
| Active Not Recruiting | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic NCT01199562 | City of Hope Medical Center | — |
| Terminated | Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leuk NCT01076556 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Canc NCT01053494 | Wake Forest University Health Sciences | N/A |
| Completed | Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia NCT01024010 | Mayo Clinic | Phase 2 |
| Terminated | Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Le NCT01649791 | Roswell Park Cancer Institute | N/A |
| Terminated | Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer NCT01044745 | University of Nebraska | Phase 2 |
| Completed | Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untrea NCT00918723 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomat NCT00602459 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemi NCT00612612 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chro NCT00563290 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT01093586 | Case Comprehensive Cancer Center | Phase 2 |
| Completed | Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem NCT00489203 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymph NCT00476047 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma NCT00377104 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Sunitinib in Treating Patients With Idiopathic Myelofibrosis NCT00387426 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Sorafenib in Treating Patients With Relapsed Chronic Lymphocytic Leukemia NCT00303966 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma NCT00288067 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia NCT00098670 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone To NCT00089011 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Man NCT00058227 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenola NCT00112593 | Fred Hutchinson Cancer Center | N/A |
| Completed | Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia NCT00003620 | National Cancer Institute (NCI) | Phase 2 |